AMCR vs DKS

AMCR's deterministic health score is stable with a Piotroski F-Score of 6/9, indicating moderate financial strength, though the absence of an Altman Z-Score limits distress risk assessment. The stock trades at a significant premium to its Graham Number ($29.87) and intrinsic value ($10.92), supported by a high forward P/E of 9.96 despite a trailing P/E of 28.38, suggesting optimism around earnings recovery. While revenue growth is robust (71.3% YoY), earnings growth is negative (-14.4% YoY), and the dividend payout ratio is dangerously high at 169.44%, raising sustainability concerns. Analysts are strongly bullish with a $55.01 target price, but weak recent earnings beats (1 of last 4) and bearish technicals (0/100) create conflicting signals.

DKS presents a conflicting profile with a stable Piotroski F-Score of 4/9 but significant valuation headwinds. While revenue growth is explosive at 59.9%, earnings growth has plummeted by 61%, creating a dangerous divergence between top-line expansion and bottom-line profitability. The stock trades at a massive premium to its Graham Number ($118.21) and Intrinsic Value ($69.72), though a low Forward P/E of 13.99 suggests analysts expect a sharp earnings recovery. Technicals and insider sentiment are currently bearish, offsetting the bullish analyst consensus.